Cargando…

Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews

BACKGROUND: There is conflicting evidence on the association between antipsychotic polypharmacy and metabolic syndrome in schizophrenia. We conducted a review of published systematic reviews to evaluate evidence on the association between metabolic syndrome (diabetes, hypertension, and hyperlipidaem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ijaz, Sharea, Bolea, Blanca, Davies, Simon, Savović, Jelena, Richards, Alison, Sullivan, Sarah, Moran, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122457/ https://www.ncbi.nlm.nih.gov/pubmed/30176844 http://dx.doi.org/10.1186/s12888-018-1848-y

Ejemplares similares

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

Nutritional deficiencies in homeless persons with problematic drinking: a systematic review
por: Ijaz, Sharea, et al.
Publicado: (2017)

Quality of family relationships and outcomes of dementia: a systematic review
por: Edwards, Hannah B, et al.
Publicado: (2018)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
por: Kamei, Hiroyuki
Publicado: (2022)

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
por: Bighelli, Irene, et al.
Publicado: (2022)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Preventing Childhood Obesity in Primary Schools: A Realist Review from UK Perspective
por: Ijaz, Sharea, et al.
Publicado: (2021)

Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?
por: Pae, Chi-Un
Publicado: (2020)

Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia
por: Yasui‐Furukori, Norio, et al.
Publicado: (2020)

Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
por: Lähteenvuo, Markku, et al.
Publicado: (2021)

Interventions for preventing or treating malnutrition in homeless problem-drinkers: a systematic review
por: Ijaz, Sharea, et al.
Publicado: (2018)

Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy
por: Yazici, Esra, et al.
Publicado: (2017)

Variations in policies for accessing elective musculoskeletal procedures in the English National Health Service: A documentary analysis
por: Rooshenas, Leila, et al.
Publicado: (2022)

Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis
por: Ayenew, Wondim, et al.
Publicado: (2021)

PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
por: Joe, Soohyun, et al.
Publicado: (2016)

Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy
por: Fisher, Maxine D, et al.
Publicado: (2014)

Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
por: Kim, Jung-Jin, et al.
Publicado: (2021)

Prescription Patterns for Patients with Schizophrenia in Korea: A Focus on Antipsychotic Polypharmacy
por: Kim, Hee-Yun, et al.
Publicado: (2014)

Antipsychotic polypharmacy in adult patients diagnosed with schizophrenia: A retrospective study
por: Patrichi, Bogdan, et al.
Publicado: (2021)

Antipsychotic Polypharmacy in Clozapine Resistant Schizophrenia: A Randomized Controlled Trial of Tapering Antipsychotic Co-treatment
por: Repo-Tiihonen, Eila, et al.
Publicado: (2012)

Evaluation of the Individual Safe Correction of Antipsychotic Agent Polypharmacy in Japanese Patients with Chronic Schizophrenia: Validation of Safe Corrections for Antipsychotic Polypharmacy and the High-Dose Method
por: Yamanouchi, Yoshio, et al.
Publicado: (2015)

Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia
por: Koricanac, Aleksandra, et al.
Publicado: (2022)

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
por: Tiihonen, Jari, et al.
Publicado: (2019)

S204. REDUCTION OF ANTIPSYCHOTIC DOSES AND POLYPHARMACY: TWO COCHRANE REVIEWS
por: Leucht, Stefan, et al.
Publicado: (2020)

Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Hjorth, Stephan
Publicado: (2021)

Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
por: Pae, Chi-Un, et al.
Publicado: (2021)

Antipsychotic Polypharmacy-Related Cardiovascular Morbidity and Mortality: A Comprehensive Review
por: Edinoff, Amber N., et al.
Publicado: (2022)

Factors related to adverse long-term outcomes after mild traumatic brain injury in children: a scoping review
por: Ijaz, Sharea, et al.
Publicado: (2023)

Characterising the evolution of antipsychotic polypharmacy and clozapine prescribing patterns in schizophrenia patients during psychiatric hospitalisations
por: Lagreula, J., et al.
Publicado: (2022)

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Antipsychotic polypharmacy prescribing and risk of hospital readmission
por: Kadra, Giouliana, et al.
Publicado: (2017)

Antipsychotic polypharmacy and associated factors among patients with schizophrenia: Multicenter cross-sectional study in Northwest Ethiopia
por: Tamene, Fasil Bayafers, et al.
Publicado: (2023)

Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
por: Misawa, Fuminari, et al.
Publicado: (2011)

Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
por: Jaberi, Nayyer, et al.
Publicado: (2020)

Medication Gaps and Antipsychotic Polypharmacy in Previously Hospitalized Schizophrenia Patients: An Electronic Cohort Study in Three Canadian Provinces
por: Peters, Evyn, et al.
Publicado: (2022)

Polypharmacy and relapse of schizophrenia: are they related?
por: Softic, R., et al.
Publicado: (2022)

Antipsychotic Polypharmacy and High-Dose Antipsychotic Regimens in the Residential Italian Forensic Psychiatric Population (REMS)
por: Mandarelli, Gabriele, et al.
Publicado: (2022)

Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
por: Singh, Raghunath, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m9pbdba90q423mb392j38jqj8q